Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.78

€8.78

-1.810%
-0.16
-1.810%
-
 
22:26 / Tradegate WKN: A3CMGM / Name: Apontis Pharma / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Apontis Pharma AG Stock

A loss of -1.810% shows a downward development for Apontis Pharma AG.

Pros and Cons of Apontis Pharma AG in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQS-News: APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQS-News: APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications